Most Recent
Most employers won’t be able to require staff to get COVID-19 vaccine
Employment 2021-02-19 11:29 pm By Cat Fredenburgh

COVID-19 vaccinations will begin this week, but most employers won’t be able to force staff to get the jab.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

IVF Australia faces multimillion dollar lawsuit over inaccurate genetic test
Competition & Consumer Protection 2021-02-17 6:32 pm By Spencer Fowler Steen

Fertility clinic IVF Australia is facing a lawsuit worth “many millions of dollars” launched by the parents of a child born with Pallister-Kilian syndrome, alleging it did not carry out a vital pre-implantation diagnostic test that would have identified the disease.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Full Court hears government’s $325M fight with Sanofi over ban on Plavix generic
Intellectual Property 2021-02-16 4:13 pm By Miklos Bolza

Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

$37.75M settlement reached in Estia Health class action
Class Actions 2021-02-16 12:48 pm By Cat Fredenburgh

A $37.75 million settlement has been reached in a shareholder class action against Estia Health that accused the aged care provider of failing to disclose difficulties in its 2015 and 2016 acquisition strategy.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Merck Sharpe & Dohme sues Sandoz to block Januvia generic
Intellectual Property 2021-02-15 9:43 pm By Spencer Fowler Steen

US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Beckman Coulter’s removal application to be heard with ‘Access’ trade mark appeal
Intellectual Property 2021-02-12 5:16 pm By Spencer Fowler Steen

US biotech company Gen-Probe’s bid for the removal of rival Beckman Coulter’s ‘Access’ trade marks will be heard alongside its appeal of a ruling from the Trade Marks Office denying the company’s bid to expand its ‘Open Access’ trade mark to Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

High Court to weigh in on $26.3M Lexapro patent judgment
High Court 2021-02-11 10:43 pm By Cat Fredenburgh

The High Court will decide whether the Full Court was wrong to overturn a $26.3 million judgment for Danish drug maker H Lundbeck in its long-running patent battle with generic drug maker Sandoz over the patent for blockbuster antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Vagisil maker wins appeal to halt European rival’s trade mark
Intellectual Property 2021-02-11 3:40 pm By Spencer Fowler Steen

The maker of Vagisil feminine hygiene products has successfully overturned a ruling that denied its bid to stop a European competitor from registering Vagisan as a trade mark in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

TGA orders ex-senator David Leyonhjelm to take down misleading COVID tweets
COVID-19 2021-02-09 1:38 pm By Spencer Fowler Steen

The TGA has ordered former senator and vet David Leyonhjelm to take down misleading tweets spruiking a medication used to treat parasite infestations in horses as “probably the most economical source” to treat COVID-19.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Death causes six-month delay of trial in Merck, Pfizer vaccine patent dispute
Intellectual Property 2021-02-03 5:18 pm By Cat Fredenburgh

The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer’s expert witnesses.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?